

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No. ANG/2425/172

Date 14.08.2024

To
Department of Corporate Services,
BSE Limited
P J Towers, Dalal Street,
Mumbai- 400001

Ref: BSE Security Code: 540694

Sub: Outcome of Board Meeting pursuant to Reg. 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

Dear Sir/Madam,

With reference to the cited subject, we would like to inform you that the Board of Directors of the Company at its meeting held on today i.e., 14th August, 2024, have inter- alia, transacted the following item(s) of the Agenda:

1. Approved the Standalone and Consolidated Un-audited Financial Result along with the Limited Review Report for the first quarter ended as at 30th June, 2024 and a copy of the same is enclosed.
2. Considered and took the note on the resignation letter received from the statutory Auditor of the company, informing their inability to continue as the Statutory Auditors of the Company. A copy of Auditor' resignation is enclosed.

Further in order to comply with SEBI circular no. CIR/CFD/CMD1/114/2019, Dated October 18, 2019, we confirm that we will receive the limited review report for the quarter ending June 2024, on 14th August 2024.

Necessary steps are being taken to appoint another Auditor which shall be intimated accordingly.

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Details with respect to resignation of Auditors of the Company as required under Regulation 30 Read with Schedule III of the Listing Regulations, SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015 and CIR/CFD/CMD1/1 14/2019 dated October 18, 2019 are as follow:


Particulars	Details
Name of the company	ANG Lifesciences India Limited
Name of the Auditor	M/s Singh Bhupinder & Associates
Reason for Change viz. appointment, resignation, removal, death or otherwise	The reason for Auditor's resignation is that the associate and trained personnel who handle the audit of IND-AS financial statement of companies have left the Auditor's firm and at present they have not find the suitable replacement for them. So therefore they will not able to carry out the statutory audit and limited reviews of our company for the next quarter/half year/annually
Effective Date of Resignation	14.08.2024

The meeting commenced at 05:30 PM and concluded at 06:20 PM

Please take the above information on your record.

Thanking you,
Yours Faithfully,

For ANG Lifesciences India Limited.


Renu Kaur
Company Secretary
A62402

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Statement of standalone unaudited results for the quarter ended 30 June 2024

(₹ in lakhs except per share data)

Particulars	Quarter ended 30 June 2024	Quarter ended 31 March 2024	Quarter ended 30 June 2023	Year ended 31 March 2024
	(Unaudited)	(Audited, as explained in note 4)	(Unaudited)	(Audited)
I Revenue from operations	1,617.67	3,407.99	5,060.80	13,136.88
II Other income	135.84	24.86	34.32	83.52
III Total revenue (I+II)	1,753.51	3,432.85	5,095.12	13,220.40
IV Expenses				
Cost of materials consumed	1,137.29	3,028.70	3,026.04	9,393.41
Changes in inventories of finished goods and work-in-progress	(51.48)	(768.59)	335.99	(673.68)
Employee benefits expense	350.49	366.56	473.71	1,590.44
Finance costs	166.94	343.58	193.78	932.77
Depreciation and amortisation expenses	151.07	182.99	193.63	775.49
Other expenses	374.07	397.41	658.17	1,915.20
Total expenses (IV)	2,128.38	3,550.66	4,881.32	13,933.63
V (Loss)/Profit before exceptional items and tax (III-IV)	(374.87)	(117.81)	213.80	(713.23)
VI Exceptional items	-	173.51	-	173.51
VII (Loss)/Profit before tax (V-VI)	(374.87)	(291.33)	213.80	(886.75)
VIII Tax expense				
(1) Current tax	-	-	81.88	0.13
(2) Deferred tax	(98.34)	69.04	(27.76)	(22.06)
Total tax expense (1+2)	(98.34)	69.04	54.12	(21.93)
IX (Loss)/Profit for the period (VII-VIII)	(276.53)	(360.36)	159.68	(864.81)
X Other comprehensive income:				
Items that will not be reclassified to profit or (loss)	-	5.50	10.81	24.88
Income tax relating to items that will not be reclassified to profit or loss	-	(1.38)	(2.72)	(6.26)
XI Total comprehensive (loss)/income (IX+X)	(276.53)	(356.24)	167.77	(846.19)
XII Paid-up equity share capital (Face value ₹ 10/- per share)	1,305.83	1,305.83	1,305.83	1,305.83
XIII Other equity				6,401.50
XIV (Loss)/Earnings per equity share (of ₹ 10/- each)				
-Basic and diluted	(2.12)	(2.73)	1.28	(6.48)

See accompanying notes to the financial results.



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Statement of consolidated unaudited results for the quarter ended 30 June 2024

(₹ in lakhs except per share data)

Particulars	Quarter ended 30 June 2024	Quarter ended 31 March 2024	Quarter ended 30 June 2023	Year ended 31 March 2024
		(Audited, as explained in note 4)		(Audited)
I Revenue from operations	1,841.00	3,783.98	5,646.25	14,610.97
II Other income	128.48	18.76	31.65	69.82
III Total revenue (I+II)	1,969.48	3,802.74	5,677.90	14,680.79
IV Expenses				
Cost of materials consumed	1,224.27	3,305.54	3,413.88	10,278.66
Changes in inventories of finished goods and work-in-progress	(57.37)	(799.27)	281.74	(767.38)
Employee benefits expense	426.41	415.11	576.48	1,935.22
Finance costs	208.34	383.91	231.41	1,095.73
Depreciation and amortisation expenses	163.32	204.65	218.81	837.14
Other expenses	418.65	526.90	719.43	2,199.28
Total expenses (IV)	2,383.62	4,036.84	5,441.75	15,578.65
V (Loss)/Profit before exceptional items and tax (III-IV)	(414.14)	(234.10)	236.15	(897.86)
VI Exceptional items	-	173.51	-	173.51
VII (Loss)/Profit before tax (V-VI)	(414.14)	(407.61)	236.15	(1,071.37)
Tax expense				
(1) Current tax	-	-	81.88	0.13
(2) Deferred tax	(106.84)	(42.94)	(20.94)	(57.19)
VIII Total tax expense (1+2)	(106.84)	(42.94)	60.94	(57.06)
IX (Loss)/Profit for the period (VII-VIII)	(307.30)	(364.66)	175.21	(1,014.31)
X Other comprehensive income:				
Items that will not be reclassified to profit or (loss)	-	7.33	11.95	27.59
Income tax relating to items that will not be reclassified to profit or loss	-	(1.84)	(3.01)	(6.94)
XI Total comprehensive (loss)/income (IX+X)	(307.30)	(359.18)	184.15	(993.66)
XII Paid-up equity share capital (Face value ₹ 10/- per share)	1,305.83	1,305.83	1,305.83	1,305.83
XIII Other equity				6,321.88
XIV (Loss)/Earnings per equity share (of ₹ 10/- each)				
- Basic and Diluted	(2.35)	(2.75)	1.41	(7.61)

See accompanying notes to the financial results.



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

As per Ind-AS 108, Operating Segments have been defined and presented based on the regular review by the Company's Chief Operating Decision Maker to assess the performance of each segment and to make decision about allocation of resources. The accounting principles used in the preparation of the consolidated unaudited financial results are consistently applied to record revenue and expenditure in individual segments. Accordingly, the consolidated unaudited segment wise revenue, results, assets, and liabilities is as follows :

S.No.	Particulars	Quarter ended			Year ended
		30 June	31 March	30 June	31 March
		2024	2024	2023	2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1	Segment revenue				
	a) Pharmaceuticals	1,617.67	3,407.98	5,060.80	13,136.88
	b) Printing and packagings	301.91	487.82	679.39	1,830.15
	Total	1,919.59	3,895.80	5,740.19	14,967.02
	Less: Inter segment revenue	78.58	111.82	93.94	356.06
	Revenue from operations	1,841.00	3,783.98	5,646.25	14,610.97
2	Segment results (profit before tax and finance cost from each segment)				
	a) Pharmaceuticals	(207.94)	225.74	407.69	219.50
	b) Printing and packagings	10.28	(70.88)	63.68	(4.88)
	Total	(197.66)	154.86	471.37	214.62
	Less: Finance costs	216.48	388.96	235.22	1,112.49
	(Loss)/Profit before tax	(414.14)	(234.10)	236.15	(897.86)
	Particulars			As at	As at
				30 June 2024	31 March 2024
				(Unaudited)	(Audited)
3	Segment Assets				
	a) Pharmaceuticals			21,072.14	20,856.95
	b) Printing and packagings			3,369.77	3,390.66
	Total Segment assets			24,441.91	24,247.61
4	Segment liabilities				
	a) Pharmaceuticals			12,197.84	14,035.25
	b) Printing and packagings			2,094.80	2,934.65
	Total Segment liabilities			14,292.64	16,969.89



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Notes:

1. ANG Lifesciences India Limited ('the Company') is a public listed company incorporated in India and is in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of Dry Powder Injection Vials, Liquid Injections Vials, Ampoules, PFS, Hard Gelatin Capsules, Tablets, Soft Gelatin Capsules, Dry Syrups, Liquid Syrups and Suspension, Lotions etc. ANG's products portfolio comprises of major therapeutic categories such as Antibiotics, Antiviral, Antimalarial, Antiulcer, Carbapenem, Corticosteroid, Penicillin, Beta Lactamase Inhibitor etc.
2. The above audited standalone and consolidated financial results for the quarter ended 30 June 2024 have been reviewed by the Audit Committee and approved by the Company's Board of Directors in their respective meetings held on 14 August 2024. The Statutory Auditors of the Company have expressed unmodified opinion on these results.
3. The above audited standalone and consolidated financial results of ANG Lifesciences India Limited ('the Company' or 'the Holding Company') and its subsidiary, Mansa Print and Publishers Limited (the Holding and the subsidiary together referred to as 'the Group') have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015, as amended and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended) and other accounting principles generally accepted in India.
4. Figures for the standalone and consolidated financial results for the quarter ended 31 March 2024 are the balancing audited figures of the full financial year and the published year to date figures upto the third quarter of the year ended 31 March 2024 which were subjected to limited review by the statutory auditors of the Company.
5. These financial results are available on the website of the Company at www.anglifesciences.com and are also available on the website of Bombay Stock Exchange at www.bseindia.com.
6. Previous period figures have been re-grouped/reclassified wherever necessary, to conform to current period's classification.

For and on behalf of the Board of Directors of
ANG Lifesciences India Limited

(Managing Director)

Place: Amritsar
Date: 14 August 2024




Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of
ANG Lifesciences India Limited

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of ANG Lifesciences India Limited ("the Company") for the quarter ended 30th June, 2024 ("the statement") attached herewith being submitted by the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended, including relevant circulars issued by the SEBI from time to time.
2. This Statement which is the responsibility of the Holding Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurements principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Singh Bhupinder & Associates
Chartered Accounts



(Bhupinder Singh)

Prop.

FRN. 035417N

M. No. 513899

UDIN: 24513899BKAEAP4225

Date: 14.08.2024

Place: Amritsar




Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of
ANG Lifesciences India Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of ANG Lifesciences India Limited ("Holding Company") and its Wholly owned subsidiary (the Holding and its Wholly owned subsidiary together referred to as "the Group", (refer point no. 5 in this Statement] for the quarter ended 30th June, 2024 ("the statement") attached herewith being submitted by the Holding Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended ("the Listing Regulations") including relevant circulars issued by the SEBI from time to time.
2. This statement which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors has been prepared in accordance with the recognition and measurements principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.
5. The Statement includes the result of the following entities:-
Mansa Print & Publishers Limited
6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Singh Bhupinder & Associates
Chartered Accountants



(Bhupinder Singh)

Prop.

FRN. 035417N

M. No. 513899

UDIN: 24513899BKAEAO9432

Date: 14.08.2024

Place: Amritsar



Date: 14.08.2024

To

The Board of Directors
ANG Lifesciences India Limited
SCO 113, Darbara Complex, B Block
Ranjit Avenue Amritsar- 143001

Sub: Resignation from the post of Statutory Auditor of the company

Sir,

This is to inform you that I/We, **M/s Singh Bhupinder & Associates**, Chartered Accountant (FRN. **035417N, M. No. 513899**) has been appointed as Statutory Auditor in your company on 30.12.2023.


We would like to state that most of our trained associates/resource personnel working on the audit of companies complying with IND AS, have left our firm. However, despite of our best effort we could neither retain these personnel nor find suitable replacements for them. In these circumstances, we state that we will not be able to carry out the statutory audit and limited reviews of your-company for the upcoming quarter/half year/annually.

Hence, we are herewith tendering our resignation forthwith as the statutory auditors of your company. We sincerely regret for the inconvenience, if any, caused to you in this regard.

I therefore request the company to consider this letter as my formal resignation from the Statutory Auditor of the company.

Please find the Annexure A, the information to be obtained by the company from the auditors for their resignation, as required by SEBI circular No. CIR/CFD/CMD1/4 14/2019, Dated October 18, 2019.

Thanking You
Yours' faithfully



Bhupinder Singh
For Singh Bhupinder & Associates
Chartered Accountants
M. No. 513899

Date: 14.08.2024
Place: Amritsar

UDIN: 24513899BKAEAN7187



Annexure A

Disclosure of Information as per Securities and Exchange Board of India circular CIR /CFD/CMD/114/2019, dated 18 October 2019

Sn	Particulars	Details
1.	Name of Company	ANG Lifesciences India Limited
2.	Details of Statutory Auditor	
	Name	M/s Singh Bhupinder & Associates, Chartered Accountant.
	Address	#2, Mishra Singh Colony, Near Medcard Hospital, Tarn Taran Road, Amritsar 143022
	Phone number	0183-5027845
	Email id	cabhupinder29@gmail.com
3.	Details of association with the listed entity/material subsidiary	
	a. Date on which the Statutory Auditor was appointed	30.12.2023
	b. Date on which the terms of the Statutory Auditor was scheduled to expire	Till the conclusion of Annual General meeting for FY 2023-24
	c. Prior to resignation, the latest audit report/limited review report submitted by the auditor and date of its submission	Limited Review Report 30.06.2024
4.	Detailed reasons for resignation	Refer resignation letter
5.	In case of any concerns, efforts made by the auditor prior to resignation (including approaching the Audit committee/Board of Directors)	NA
6.	In case the information requested by the auditor was not provided, then following shall be disclosed	NA
	a. Whether the inability to obtain sufficient appropriate audit evidence was due to a management imposed limitation or circumstances beyond the control of the management	-
	b. Whether the lack of information would have significant impact on the financial statements/results	-
	c. Whether the auditor has performed alternatives procedures to obtain appropriate evidence for the purpose of audit/limited review as laid down in SA 705 (Revised)	-
	d. Whether the lack of information was prevalent in the previous reported financial statements/results. If yes, on what basis the previous audit/limited review report were issued	-
7.	Any other facts relevant to the resignation	None

Declaration

- 1. We hereby confirm that the information given in this letter and its attachments is correct and complete*
- 2. We hereby confirm that there are no other material reasons other than those provided above resignation of our firm*

